+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A pathologist's look at infectious diseases: selection by AIDS and other infections, clinical types of immunities and vaccine expectations



A pathologist's look at infectious diseases: selection by AIDS and other infections, clinical types of immunities and vaccine expectations



American Journal of Tropical Medicine and Hygiene 40(4): 335-343



The role of natural selection in shaping populations to withstand infectious diseases and the nature of immunity developed against individual infections, and the future of vaccines are discussed in this paper. The main topics considered include the challenges and novel phenomena caused by the appearance of AIDS and the different types and degrees of clinical immunity against various infections including such protozoal diseases as malaria, toxoplasmosis, trypanosomiasis and leishmaniasis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 001740535

Download citation: RISBibTeXText

PMID: 2653059


Related references

Recovery of humoral and cellular immunities to vaccine-preventable infectious diseases in pediatric oncology patients. Pediatric Hematology and Oncology 27(3): 195-204, 2010

Incidence and clinical relevance of anaerobic bacterial infections in patients with AIDS at an infectious diseases institute. Clinical Infectious Diseases 20(Suppl. 2): S212-S213, 1995

Supplement 2. Abraham I. Braude Memorial Symposium on Infectious Diseases || Clinical Impact of Cytomegalovirus Infections of the Nervous System in Patients with AIDS. Clinical Infectious Diseases 21: S196-S201, 1995

Selection criteria of organ donors with respect to infectious disease transmission. Study Group on Infections in Transplantation (GESITRA). Spanish Society of Infectious Diseases and and Clinical Microbiology (SEIMS). National Organization of Transplantation (ONT). Ministry of Health Services. Medicina Clinica 112(18): 711-715, 1999

A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Journal of Infectious Diseases 173(2): 330-339, 1996

The Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health. Clinical Infectious Diseases 58(7): 991-996, 2015

Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine 16(5): 493-506, 1998

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Aids Research and Human Retroviruses 15(2): 115-132, 1999

Summary of the workshop on future directions in discovery and development of therapeutic agents for opportunistic infections associated with aids sponsored by the division of aids and the division of microbiology and infectious diseases national institute of allergy and infectious disease and the national institutes of health rockville maryland usa september 11 12 1989. Journal of Infectious Diseases 164(2): 245-251, 1991

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. Journal of Leukocyte Biology 58(1): 1-13, 1995

Preparations for HIV vaccine efficacy trials. Vaccine selection guidelines. National Institute of Allergy and Infectious Diseases, National Institutes of Health. Aids Research and Human Retroviruses 10(Suppl. 2): S295-S296, 1994

NIAID HIV/AIDS vaccine research. National Institute of Allergy and Infectious Diseases. Niaid Aids Agenda: 4-4, 1997

Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. Journal of Infectious Diseases 168(6): 1387-1395, 1993

NIAID launches three new AIDS vaccine trials. National Institute of Allergy and Infectious Diseases. Niaid Aids Agenda: 3-3, 1995

The patient with impaired defense against infections. Types of defect and spectrum of infectious diseases. Tidsskrift for den Norske Laegeforening 103(3): 213-219, 1983